Tenfold Overdose in the Hazardous Drug Hood

Multiple independent failures, each sufficient on its own to stop production.

• Facility/equipment: replacing a component of the primary engineering control requires recertification before use, and certification is required on a routine interval (at least every 6 months) regardless. Compounding in an uncertified hood after a filter change is not defensible.
• Hazardous drug handling: 5-FU requires hazardous-drug PPE - a chemo-rated gown, double gloves, eye/face protection - plus engineering controls and a closed system transfer device for administration/preparation where appropriate. A lab coat is not acceptable PPE; backorder is a supply problem to solve, not a reason to expose staff.
• Pregnancy: a pregnant worker is not automatically barred from hazardous drug work, but she must be informed of the reproductive risks and offered accommodation/reassignment. Assigning her without that conversation is a management failure.
• Pharmacist verification: final verification of a compounded sterile preparation must be performed by a pharmacist who can actually inspect the product and the compounding process - not from a photograph while running a register. Verification of a 10x concentration error is exactly what that requirement exists to prevent.

Action: suspend hazardous compounding until the hood is recertified, PPE and CSTD stock are restored, and staffing allows real pharmacist oversight.

Patient safety first, then disclosure, then documentation - all before any discussion of blame.

1. Clinical: quantify the actual dose received, contact the prescriber and the oncology team immediately, and initiate an adverse-event assessment (5-FU toxicity: mucositis, myelosuppression, diarrhea, neurotoxicity). Escalate to the emergency department if indicated.
2. Disclosure: tell the patient (or the appropriate decision-maker) what happened, in plain language, promptly. Concealment converts a systems error into a professional-conduct problem.
3. Internal reporting: file the institution's medication-event/patient-safety report, preserve the product, the label photograph, the order, the compounding record, and the hood logs, and begin root-cause analysis (concentration calculation, independent double-check, verification workflow).
4. External: as a hospital event, report through the facility's patient-safety reporting obligations to DPH; notify the pharmacy's insurer and, if the event meets the threshold, evaluate whether Board notification is required. A single dispensing error is generally handled through the patient, prescriber, and facility reporting channels - but falsifying or destroying records about it is an independent Board violation.

Both statements are wrong, and one does not excuse the other.

• Final verification is non-delegable. A technician may prepare; a pharmacist must verify. A technician cannot lawfully perform the final check, and a pharmacist cannot ratify one after the fact. The technician's role is limited to tasks the Board permits and the pharmacist delegates; preparation of a hazardous sterile dose without competency validation and appropriate supervision compounds the problem.
• Staffing is not a defense. "The only one on duty" is a management condition created by the pharmacist-in-charge and the employer. The correct response to insufficient staffing for a sterile compounding operation is to stop compounding, not to weaken verification. The Board evaluates the licensee's exercise of judgment, and pressure from an employer does not transfer the duty.
• Accountability: the pharmacist who verified is directly responsible; the PIC is responsible for systems, training, certification schedules, PPE supply, and staffing; the employer bears corporate responsibility. All three are legitimate subjects of an internal investigation, and the PIC's failure to maintain certification and PPE may itself be reportable conduct.